// App-Quantinova.ai

: BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).

Researchers

Presenter

  • Jason J. Luke

Principal Investigators

  • Anthony Joshua

  • Jayesh Desai

  • Andrea I. Varga

  • Victor Moreno

  • Carlos A. Gomez-Roca

  • Ben Markman

  • Filippo G. De Braud

  • Sandip Pravin Patel

  • Matteo S. Carlino

  • Lillian L. Siu

  • Giuseppe Curigliano

  • Zhaohui Liu

  • Yuko Ishii

  • Megan Wind-Rotolo

  • Paul Andrew Basciano

  • Alex Azrilevich

  • Karen A. Gelmon

Medical Centers

  • University of Chicago Comprehensive Cancer Center, Chicago, IL

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • The Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

  • Gustave Roussy Cancer Campus, Villejuif, France

  • Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

  • Institut Universitaire du Cancer de Toulouse, Toulouse, France

  • Monash Health and Monash University, Melbourne, Australia

  • Division of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, Australia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • University of Milan, Istituto Europeo di Oncologia, Milano, Italy

  • Bristol-Myers Sqiubb, Princeton, NJ

  • University of British Columbia and BC Cancer Agency, Vancouver, BC, Canada

Locations

  • United States

  • Spain

  • Australia

  • France

  • Italy

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT02658890

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved